Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial-Reference-Cited by-同舟云学术

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Published:2021-12 Issue: Volume: Page:
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Ren Shengxiang,Chen Jianhua,Xu Xingxiang,Jiang Tao,Cheng Ying,Chen Gongyan,Pan Yueyin,Fang Yong,Wang Qiming,Huang Yunchao,Yao Wenxiu,Wang Rui,Li Xingya,Zhang Wei,Zhang Yanjun,Hu Sheng,Guo Renhua,Shi Jianhua,Wang Zhiwu,Cao Peiguo,Wang Donglin,Fang Jian,Luo Hui,Geng Yi,Xing Chunyan,Lv Dongqing,Zhang Yiping,Yu Junyan,Cang Shundong,Yang Zeyu,Shi Wei,Zou Jianjun,Zhou Caicun

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference32 articles.

1. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment;Duma;Mayo Clin Proc,2019

2. Current and emergent therapy options for advanced squamous cell lung cancer;Socinski;J Thorac Oncol,2018

3. Chinese Guidelines for Diagnosis and Treatment of Primary Lung cancer 2018 (English Version);Chin J Cancer Res,2019

4. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–small-cell lung Cancer;Reck;N Engl J Med,2016

5. Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC;Herbst;N Engl J Med,2020

Cited by 155 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of gemcitabine/nab-paclitaxel combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer;International Immunopharmacology;2024-09

2. Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial;BMC Medicine;2024-08-26

3. Genomic correlates of the response to first-line PD-1 blockade plus chemotherapy in patients with advanced non-small-cell lung cancer;Chinese Medical Journal;2024-08-21

4. Toxicity profile of camrelizumab-based immunotherapy in older adults with advanced cancer;Scientific Reports;2024-08-16

5. Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer;Cochrane Database of Systematic Reviews;2024-08-13